Atorvastatin is a statin drug, which is used to lower blood cholesterol levels. This common drug is mainly used to treat high cholesterol, hyperlipidemia, and coronary heart disease. The original drug Atorvastatin was developed by Pfizer Pharmaceuticals under the trade name LIPITOR. According to CRI’s analysis, Lipitor entered the Chinese market in 1999, and then some Chinese local companies’ generic drugs were successively listed. Pfizer Pharmaceuticals still accounts for the most market share in China by 2020.


According to CRI’s market research, the sales value of Atorvastatin in the Chinese market increased from 2016 to 2018. In 2019, due to being included in the Chinese government’s "4+7" policy for drug centralized procurement, the price of the drug fell sharply, resulting in a year-on-year decrease of 18.33% in its sales value. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of the hospital, the sales value of Atorvastatin in the Chinese market in 2020 dropped to CNY825 million, and the CAGR is about -20.30% from 2016 to 2020.


CRI expects that with the effective relief of COVID-19, the sales value of Atorvastatin in the Chinese market will have a restorative growth from 2021 to 2025. In addition, the seventh census showed that as of the end of 2020, the total population of China was 1,411.78 million, and the population of 60 years and over was 264.02 million, accounting for 18.70% of the total population. It is expected that the elderly population in China will show an increasing trend. The proportion of the elderly population will continue to rise, and the incidence of cardiovascular diseases will continue to rise accordingly. In addition, as the pace of life of Chinese residents accelerates, unhealthy lifestyles increase the risk of blood lipid diseases and expand the market for Atorvastatin. Therefore, CRI predicts that sales value of Atorvastatin in the Chinese market will continue to grow from 2021 to 2025.